MexicoTuberculosis profile
Population  2014 125 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.1 (2.1–2.1) 1.7 (1.7–1.7)
Mortality (HIV+TB only) 0.31 (0.24–0.38) 0.24 (0.19–0.3)
Prevalence  (includes HIV+TB) 33 (15–58) 27 (12–46)
Incidence  (includes HIV+TB) 26 (23–29) 21 (19–23)
Incidence (HIV+TB only) 2.1 (1.9–2.4) 1.7 (1.5–1.9)
         
Case detection, all forms (%) 81 (72–91)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.4 (2.1–2.8) 6.5 (5.1–7.8)
MDR-TB cases among notified pulmonary
TB cases
390 (340–450) 110 (84–130)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 13 177   779
Pulmonary, clinically diagnosed 3 060   192
Extrapulmonary 3 892   96
       
Total new and relapse 21 196    
Previously treated, excluding relapses 685    
Total cases notified 21 881    
Among 21 196 new and relapse cases:
788 (4%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 42 (<1%) 1 282 (73%) 1 324
Laboratory-confirmed RR-/MDR-TB cases     201
Patients started on MDR-TB treatment ***     206
TB/HIV 2014 Number (%)
TB patients with known HIV status 18 547 (85)
HIV-positive TB patients 1 287 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 900 (70)
HIV-positive TB patients on antiretroviral therapy (ART) 755 (59)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 487  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (80) 20 708
Previously treated cases, excluding relapse, registered in 2013 (55) 638
HIV-positive TB cases, all types, registered in 2013 (48) 1 230
RR-/MDR-TB cases started on second-line treatment in 2012 (74) 133
XDR-TB cases started on second-line treatment in 2012   2
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 2.6
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 39
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 17
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-25 Data: www.who.int/tb/data